| Abstrakt: |
A patent has been issued for methods of altering bone growth by administering a Sclerostin or Wise antagonist or agonist. The patent, filed by Ossifi-Mab LLC, describes various embodiments of the invention, including promoting local bone growth, implantable medical devices, and protecting the kidney from chemical injury. The inventors aim to increase bone mineralization and treat conditions such as osteoporosis and bone fractures. The patent also mentions the use of calcium phosphate particles and ceramic compositions for filling bone defects. The patent describes methods for altering bone growth by administering antiresorptive drugs in combination with a sclerostin-recognizing antibody. The antiresorptive drugs mentioned include bisphosphonates, selective estrogen receptor modulators (SERMs), calcitonin, Vitamin D, Rank-L antagonists, denosumab, and combinations thereof. The patent claims that serial administration of these drugs can result in increased bone density and bone formation in individuals with conditions such as osteoporosis or low bone density. The patent also mentions specific formulations and administration methods for the drugs. [Extracted from the article] |
